Underscoring Critical Role of Science in a Smoke-Free Future, Philip Morris International Brings on Former Sanofi Exec as Chi...
January 11 2021 - 9:00AM
Business Wire
Philip Morris International Inc. (PMI) (NYSE: PM) today
announced the appointment of Jorge Insuasty to the position of
Chief Life Sciences Officer, effective Jan. 15, 2021. Mr. Insuasty
will report to the company’s CEO, André Calantzopoulos.
“Jorge’s wealth of experience across both the pharmaceutical and
consumer healthcare industries makes him the ideal candidate to
succeed John O’Mullane, who is retiring,” said Calantzopoulos.
“Jorge is a transformational leader in science and medicine and
excels in driving product portfolio development through to market
success. Science and a consumer-focused product portfolio are the
cornerstones of our ambition to replace cigarettes with products
that are a better choice than continued smoking. Jorge’s impressive
track record will help ensure we reach our goals and take full
advantage of adjacent revenue-generating opportunities.”
Mr. Insuasty joins PMI from Sanofi S.A., where most recently he
was the Global Franchise Head of Immunology, Oncology, and
Neurology for Sanofi Genzyme. During his nine-year tenure at Sanofi
he led the company’s product pipeline strategy, from candidate
selection through the development and regulatory review processes,
with a dozen novel drugs approved. He orchestrated significant
transformational change within the R&D and commercial functions
to substantially increase speed and efficiency, fostered external
collaboration and innovation, and was highly engaged with the
investor community. Overall, he played a pivotal role in the
turnaround of Sanofi’s R&D efforts.
Prior to Sanofi, Mr. Insuasty spent eight years at Novartis
International AG as Global Head of Development, Neuroscience, and
Ophthalmology. Before that, he was VP, Research and Development,
Consumer Medicines at Bristol Myers Squibb. Mr. Insuasty holds an
MD in cardiology from the University of Paris.
“I am very excited to join PMI,” said Insuasty. “The company’s
transformation, and smoke-free vision represent a tremendous public
health opportunity and a business challenge, both of which I will
be thrilled to contribute toward. And I also look forward to
developing adjacent future growth drivers.”
This appointment follows the recent announcement that John
O’Mullane, PMI’s current Chief Life Sciences Officer, will
retire.
“We thank John for the enormous contributions he has made these
last two years, driving innovation and rigor into our life sciences
function, and we wish him well in his retirement,” added
Calantzopoulos.
Philip Morris International: Delivering a Smoke-Free
Future
Philip Morris International (PMI) is leading a transformation in
the tobacco industry to create a smoke-free future and ultimately
replace cigarettes with smoke-free products to the benefit of
adults who would otherwise continue to smoke, society, the company,
and its shareholders. PMI is a leading international tobacco
company engaged in the manufacture and sale of cigarettes, as well
as smoke-free products and associated electronic devices and
accessories, and other nicotine-containing products in markets
outside the U.S. In addition, PMI ships a version of its IQOS
Platform 1 device and its consumables to Altria Group, Inc. for
sale under license in the U.S., where the U.S. Food and Drug
Administration (FDA) has authorized their marketing as a modified
risk tobacco product (MRTP), finding that an exposure modification
order for these products is appropriate to promote the public
health. PMI is building a future on a new category of smoke-free
products that, while not risk-free, are a much better choice than
continuing to smoke. Through multidisciplinary capabilities in
product development, state-of-the-art facilities, and scientific
substantiation, PMI aims to ensure that its smoke-free products
meet adult consumer preferences and rigorous regulatory
requirements. PMI’s smoke-free product portfolio includes
heat-not-burn and nicotine-containing vapor products. As of Sept.
30, 2020, PMI estimates that approximately 11.7 million adult
smokers around the world have already stopped smoking and switched
to PMI’s heat-not-burn product, available for sale in 61 markets in
key cities or nationwide under the IQOS brand. For more
information, please visit www.pmi.com and www.pmiscience.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210111005569/en/
David Fraser Philip Morris International T. +41 (0)79 843 8603
E. david.fraser@pmi.com
Philip Morris (NYSE:PM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Philip Morris (NYSE:PM)
Historical Stock Chart
From Apr 2023 to Apr 2024